Recent News

Archived

Micron signs research agreement with leading biotech company

ATLANTA, March 2, 2017 – Micron Biomedical, Inc. and an Asia-based biotechnology company enter into a research collaboration to evaluate Micron’s technology for administration of the company’s ground-breaking therapeutics platform technology that can be applied to treat a variety of diseases. The terms of the collaboration are confidential.

Micron enters into collaboration with top-5 pharmaceutical company

ATLANTA, December 1, 2016 – Micron Biomedical’s Vice President, R&D, Devin McAllister, PhD,  announces the signing of a research agreement between Micron and a leading global pharmaceutical company.  Under the research agreement, Micron will develop a novel microneedle patch concept to be evaluated in pre-clinical studies. The terms of the collaboration are confidential.

Micron receives Phase 1 SBIR contract from CDC

ATLANTA, September 6, 2016 – The Centers for Disease Control and Prevention (CDC) awards Micron Biomedical, Inc. a Phase 1 SBIR contract for the development of a microneedle patch for delivery of a proprietary inactivated rotavirus vaccine (IRV) developed by the CDC to overcome safety and efficacy issues associated with currently-licensed oral rotavirus vaccines in…

CDC awards Micron research contract to develop a patch for co-administration of IRV and IPV

ATLANTA, September 1, 2016 – Micron Biomedical, Inc. signs a research contract with the Centers for Disease Control and Prevention (CDC) to fund the development of a dissolving microneedle patch for the co-administration of inactivated rotavirus vaccine (IRV) and inactivated polio vaccine (IPV).  The goals of the contract are the design and development of an…

GRA Ventures Phase II Grant

Mark Prausnitz, Regents’ Professor at Georgia Tech, was recently awarded a $200,000 GRA Ventures Phase II grant to advance commercialization of microneedle patch technology. Read More…

Micron announces collaboration with leading biopharmaceutical company

ATLANTA, February 12, 2016 -Micron Biomedical, Inc. announces that it has entered into a research agreement with a leading European biopharmaceutical company to assess the suitability of its microneedle patch technology for delivery of the company’s nucleic acid platform technology.  The name of the company and the terms of the agreement are confidential.

Georgia Bio’s 2016 Innovation Awards

Regents’ Professor Mark Prausnitz has been selected as one of three recipients of Georgia Bio’s 2016 Innovation Awards. Read More…

2015 Startups to Watch Award

Micron Biomedical, a start-up company founded at Georgia Tech by Mark Prausnitz, Devin McAllister and Sebastien Henry, won the 2015 Startups to Watch Award given to university start-up companies by the Metro Atlanta Chamber of Commerce and the Atlanta Business Chronicle. Read More…

Bill & Melinda Gates Foundation Grant

The Georgia Institute of Technology and Micron Biomedical have been awarded $2.5 million in grants from the Bill & Melinda Gates Foundation to advance the development of dissolvable microneedle patches for polio immunization.  The patches will be studied to evaluate their potential role as part of the worldwide efforts to eradicate polio. Read More…

National Academy of Inventors

Mark Prausnitz, a Regents’ Professor in the School of Chemical & Biomolecular Engineering, has been elected a Fellow of the National Academy of Inventors (NAI). He joins an elite group of just 414 NAI Fellows worldwide.  The designation honors those who “have demonstrated a highly prolific spirit of innovation in creating or facilitating outstanding inventions that have made a tangible…